Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425159 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
A Phase 2 study of Generalized Epilepsy, sponsored by Biohaven Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
- 20
- Study locations
NCT06425159 is a Phase 2 study of Generalized Epilepsy that is active but no longer recruiting, run by Biohaven Therapeutics. The registered enrollment target is 242 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06425159, a Phase 2 study of Generalized Epilepsy, is active but no longer recruiting, sponsored by Biohaven Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BHV-7000
Study Locations (20)
Florida
- Nova Clinical Research, LLC - Bradenton
- University of Florida (Jacksonville) - Jacksonville
- Y&L Advance Health Care,Inc d/b/a Elite Clinical Research - Miami
- Serenity Research Center - Miami
- Research Institute of Orlando - Orlando
- Comprehensive Neurology Clinic - Orlando
- Knight Neurology - Rockledge
- Santos Research Center - Tampa
- Encore Medical Research of Weston LLC. - Weston
Arizona
- Barrow Neurological Institute - Phoenix
- ARENSIA Exploratory Medicine - Phoenix
- Center for Neurosciences - Tucson
Illinois
- Northwestern Medical Group, Department of Neurology - Chicago
- Revive Research Institute, Inc. - Elgin
Alabama
- Accel Research - Birmingham
California
- Profound Research LLC - Pasadena
District of Columbia
- Medstar Health Research Institute - Washington D.C.
Georgia
- Augusta University - Augusta
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425159
The ClinicalTrials.gov registry entry for NCT06425159 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06425159 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT06425159 about?
NCT06425159 is a clinical study titled "A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures". The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
What is the current status of trial NCT06425159?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2024-06-20. Estimated completion is 2027-07.
What conditions does trial NCT06425159 study?
This clinical trial studies the following conditions: Generalized Epilepsy.
What interventions are being tested in trial NCT06425159?
The interventions under investigation include: Placebo (DRUG), BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06425159?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425159 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.